Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.
Issue link: http://outpatientsurgery.uberflip.com/i/731766
4 4 S U P P L E M E N T T O O U T P A T I E N T S U R G E R Y M A G A Z I N E O C T O B E R 2 0 1 6 pleted or ask if something has already been done. That's why it's important to decide on emergency response assignments during drills or tabletop discussions, so there's no confusion when every second matters. We met as a team, reviewed our protocols and considered everyone's suggestions before coming up with roles and responsibilities for every person in our department. We noted the assignments on cards that are handed to responding staff mem- bers who use the handy reference to focus only on what they need to accomplish (see "Assignment Cards Ensure Organized Response"). Keep the cards, which should be laminated for durability and easy cleaning, in a 3-ring binder on the MH cart. During an emergency response, the cards can be removed and distrib- uted to the first respond- ing team members. The remaining cards are handed to other care- givers as they enter the room to help. Don't for- get about asking your Important Safety Information The use of The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital signs monitored. If patients judged malignant hype If patients judged malignant hyperthermia susceptible are administered dantrolene sodium preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible regimen, including the avoidance of known triggering agents. Monitoring for early clinical and metabolic signs of malignant hyperthermia is indicated because attenuation of malignant hyperthermia, rather than prevention, is possible. Despite initial satisfacto Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve patients who could not be weaned from dantrolene after initial treatment. The administration of i.v. dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and dizziness. There have been reports of thrombophlebitis following administration of intravenous dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions (pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap hypersensitivity type may occur with dantrolene sodium therapy. To see the full prescribing information visit www.revonto.com. © 2016 US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC. REV-P80A-1215 *from the date of manufacture † or until solution is clear ® 36 month shelf life* Ready to administer in 20 seconds † Are You Prepared for a CRISIS? Visit www.revonto.com or call (877) 411-USWM (8796) to learn more about Revonto and to see the full Prescribing Information.